好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Establishing Clinical Trial Readiness of the Rett Syndrome Hand Function Measure
Child Neurology and Developmental Neurology
P1 - Poster Session 1 (5:30 PM-6:30 PM)
7-034
To validate a video-documented hand function measure for Rett syndrome research.

Rett syndrome, a neurodevelopmental disorder caused by MECP2 mutations, is associated with loss of purposeful hand function. The Rett Syndrome Hand Function Scale (RSHFS), an 8-level scale assessing ability to grasp and manipulate objects, is used to support consistent evaluation of standardized video footage.1

A Rett expert working group finalized scripts and training materials for standardized family video recordings of hand function for RSHFS rating. Video recordings were IRB approved. Expert clinician and family feedback was used to strengthen protocol feasibility and interpret functionally meaningful change. We conducted preliminary inter-rater reliability testing with 8 raters and 23 videos of subjects for >80% power to detect kappa ≥0.5. 

Participants reached consensus on 2 levels of meaningful hand function improvement: First, progressing from no or assisted grasp (RSHFS 1–3) to unassisted ulnar or raking grasp (RSHFS 4–5); second, progressing further to higher RSHFS levels (pincer grasp, transfer between hands, and good approximation of hand position to object size). Rater scores were compared with established ratings with a mean (95%CI) weighted Kappa statistic above 0.5 and Fleiss Kappa of 0.52.

A standardized video recording of hand function by parents is feasible, and consensus was reached regarding a meaningful change in hand skills. Given that gains in hand function are rare in classic Rett syndrome, any consistent improvement in a clinical trial may indicate therapeutic benefit. Clinicians can be readily trained in assessing video-recorded hand function using the RSHFS and achieve moderate inter-rater reliability after short-term training. We are optimizing training material and conducting further inter- and intra-rater reliability testing. The availability of a validated, harmonized outcome measure is expected to accelerate progress towards better treatments for Rett syndrome.

 

1Downs J, Dev Med Child Neurol 2010;52:817-23

Authors/Disclosures

PRESENTER
No disclosure on file
Timothy A. Benke, MD, PhD The institution of Dr. Benke has received research support from NIH, RSRT, IRSF and Children's Hospital Colorado. The institution of Dr. Benke has received research support from Acadia, GW, RSRT, Ovid/Takeda, Marinus. The institution of Dr. Benke has received research support from Acadia, CUREGRI, GRINtherapeutics, GW, IRSF, Marinus, Neurogene, Taysha, Ultragenyx and Zogenix/UCB; .
No disclosure on file
Douglas Feltner No disclosure on file
Petra Kaufmann, MD, FAAN (Affinia Therapeutics) Dr. Kaufmann has received personal compensation for serving as an employee of Affinia Therapeutics. Dr. Kaufmann has received personal compensation for serving as an employee of Vigil Neuroscience. Dr. Kaufmann has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for DTx. Dr. Kaufmann has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Taysha Gene Therapies. Dr. Kaufmann has stock in Vigil Neuroscience. The institution of an immediate family member of Dr. Kaufmann has received research support from Cystic Fibrosis Foundation . Dr. Kaufmann has a non-compensated relationship as a Member of a Scientific Advisory Board with NIH that is relevant to AAN interests or activities.
David N. Lieberman, MD, PhD (Boston Children'S Hospital) Dr. Lieberman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia Pharmaceuticals. Dr. Lieberman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Taysha Gene Therapies. Dr. Lieberman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurogene.
No disclosure on file
No disclosure on file
Bryan McGill, MD, PhD (Astellas Pharma Global Development, Inc.) Dr. McGill has received personal compensation for serving as an employee of Novartis. Dr. McGill has received personal compensation for serving as an employee of AveXis. Dr. McGill has received stock or an ownership interest from Novartis.
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Alan K. Percy, MD, FAAN Dr. Percy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia Pharmaceuticals. Dr. Percy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Taysha Gene Therapies. Dr. Percy has received personal compensation in the range of $0-$499 for serving as a Consultant for Neurogene. Dr. Percy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Taysha Gene Therapies. Dr. Percy has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for IOS Press.
Daniel C. Tarquinio, DO The institution of Dr. Tarquinio has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis.
No disclosure on file